Showing results (21-30 of 42) with videos related to
Sort By:
Pageof 5
Research Square|June 3, 2024
CoCo-ST: Comparing and Contrasting Spatial Transcriptomics data sets using graph contrastive learningMuhammad Aminu, Bo Zhu, Natalie Vokes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistanceGeorge N Naumov, Monique B Nilsson, Tina Cascone, et al.Nature Cell Biology|October 13, 2025
CoCo-ST detects global and local biological structures in spatial transcriptomics datasetsMuhammad Aminu, Bo Zhu, Natalie Vokes, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2026
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitorsXimeng Liu, Moses Stamboulian, Maxime Borgeaud, et al.Science Translational Medicine|September 4, 2020
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint componentsMonique B Nilsson, Huiying Sun, Jacqulyne Robichaux, et al.Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.Nature Medicine|April 25, 2018
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLCXiuning Le, Sonam Puri, Marcelo V Negrao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2017
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung CancerTina Cascone, Li Xu, Heather Y Lin, et al.Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.Pageof 5